Zobrazeno 1 - 10
of 4 207
pro vyhledávání: ''
Autor:
Akash Roy, Nipun Verma, Ajay Duseja, Dibya L. Praharaj, Radha K. Dhiman, Madhumita Premkumar, Sunil Taneja
Publikováno v:
J Clin Exp Hepatol
BACKGROUND: Spontaneous bacterial peritonitis (SBP) heralds increased mortality in cirrhosis, mandating strategies for prophylaxis. Norfloxacin has been the recommended choice for SBP prevention. However, its use has raised concerns about antibiotic
Publikováno v:
The Lancet Gastroenterology & Hepatology. 7:161-170
Summary Background There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-
Autor:
Tomoaki Nakajima, Keizo Anzai, Atsushi Kawaguchi, Osamu Kurai, Yoshihito Kubotsu, Ayako Takamori, Hirokazu Takahashi, Michihiro Nonaka, Hideyuki Hyogo, Masafumi Ono, Satoshi Oeda, Miwa Kawanaka, Yuichiro Eguchi, Kenichi Tanaka, Kento Imajo, Masato Yoneda, Masayoshi Kage, Shinichi Aishima, Takaomi Kessoku, Yoichiro Kitajima, Ryo Tajiri, Atsushi Nakajima, Hiroshi Isoda, Hideki Fujii
Publikováno v:
Hepatology Communications, Vol 6, Iss 1, Pp 120-132 (2022)
Hepatology Communications
Hepatology Communications
Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAF
Publikováno v:
Journal of Hepatology. 76:86-92
Background & Aims Infliximab has been associated with drug-induced liver injury (DILI), particularly drug-induced autoimmune hepatitis (DIAIH). DIAIH is commonly treated with corticosteroids, but there is limited data on the efficacy of corticosteroi
Autor:
Jennifer Foulke-Abel, Kelli F. Johnson, Mark Donowitz, Ruxian Lin, Nicholas C. Zachos, Sun Lee, Varsha Singh, Jianyi Yin, Huimin Yu, Yan Rong, Julie In
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 13, Iss 1, Pp 219-232 (2022)
Cellular and Molecular Gastroenterology and Hepatology
Cellular and Molecular Gastroenterology and Hepatology
Background & Aims One of the features of ulcerative colitis (UC) is a defect in the protective mucus layer. This has been attributed to a reduced number of goblet cells (GCs). However, it is not known whether abnormal GC mucus secretion also contribu
Autor:
Miklós Sahin-Tóth, Zsanett Jancsó, Anna Orekhova, Andrea Geisz, Dóra Mosztbacher, Balazs Csaba Nemeth, Alexandra Demcsák
Publikováno v:
Am J Physiol Gastrointest Liver Physiol
The activation peptide of mammalian trypsinogens typically contains a tetra-aspartate motif (positions P2–P5 in Schechter–Berger numbering) that inhibits autoactivation and facilitates activation by enteropeptidase. This evolutionary mechanism pr
Autor:
Annarosa Floreani, Sara De Martin
Publikováno v:
Digestive and Liver Disease. 53:1531-1538
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive fibro-stenotic strictures and destruction of the biliary tree. Currently, there is no effective treatment which can delay its progression or amel
Publikováno v:
JGH Open, Vol 5, Iss 11, Pp 1298-1305 (2021)
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
Background and Aim Acute kidney injury (AKI) is a life‐threatening complication of liver cirrhosis. Here, we evaluated the risk factors and characteristics of AKI in cirrhosis. Patients/Methods This was a single‐center retrospective study. A tota
Autor:
Alexandra Cheng, Kirstin Strathie, Zebib Habtemariam, Charles Kelleher, James Lovendoski, H Lewis, Luke D Tyson
Publikováno v:
European Journal of Gastroenterology & Hepatology. 34:567-575
Patients with alcohol use disorder (AUD) and liver cirrhosis benefit from stopping alcohol intake. Baclofen has been trialled for AUD in cirrhosis and appears to be effective. However, in patients without cirrhosis acamprosate is safer and more effic
Autor:
Joy Peter, Larry Michael, Rakesh Tripathi, Gurjit S. Sidhu, Ryan Tamashiro, Lois Larsen, Gary P. Wang, Jens Kort, David R. Nelson, Gretja Schnell, Joan A. Whitlock, Michael W. Fried, Layla Schuster, Ken Bergquist, Chandni B. Patel, Ashley Magee
Publikováno v:
Journal of Hepatology. 75:820-828
Background & Aims Retreatment with glecaprevir/pibrentasvir (G/P) resulted in a rate of sustained virologic response 12 weeks after treatment completion (SVR12) of >90% in HCV genotype 1 (GT1) patients who previously failed a regimen of sofosbuvir pl